nodes	percent_of_prediction	percent_of_DWPC	metapath
Methamphetamine—SLC22A3—Melphalan—breast cancer	0.172	0.589	CbGbCtD
Methamphetamine—CYP2D6—breast cancer	0.147	1	CbGaD
Methamphetamine—L-Phenylalanine—Melphalan—breast cancer	0.122	0.405	CrCrCtD
Methamphetamine—Benzphetamine—Toremifene—breast cancer	0.11	0.365	CrCrCtD
Methamphetamine—Benzphetamine—Tamoxifen—breast cancer	0.0689	0.229	CrCrCtD
Methamphetamine—SLC22A3—Irinotecan—breast cancer	0.0583	0.199	CbGbCtD
Methamphetamine—CYP2D6—Idarubicin—breast cancer	0.0255	0.0875	CbGbCtD
Methamphetamine—CYP2D6—Vinorelbine—breast cancer	0.0125	0.0427	CbGbCtD
Methamphetamine—CYP2D6—Tamoxifen—breast cancer	0.0113	0.0386	CbGbCtD
Methamphetamine—CYP2D6—Vinblastine—breast cancer	0.00769	0.0263	CbGbCtD
Methamphetamine—CYP2D6—Doxorubicin—breast cancer	0.00472	0.0162	CbGbCtD
Methamphetamine—Digestion impaired—Fulvestrant—breast cancer	0.00307	0.0383	CcSEcCtD
Methamphetamine—SLC18A1—adrenal gland—breast cancer	0.00244	0.0508	CbGeAlD
Methamphetamine—Digestion impaired—Anastrozole—breast cancer	0.00237	0.0296	CcSEcCtD
Methamphetamine—TAAR1—female reproductive system—breast cancer	0.00235	0.0489	CbGeAlD
Methamphetamine—SLC18A1—endocrine gland—breast cancer	0.00212	0.0441	CbGeAlD
Methamphetamine—Digestion impaired—Chlorambucil—breast cancer	0.00182	0.0227	CcSEcCtD
Methamphetamine—Digestion impaired—Melphalan—breast cancer	0.00159	0.0198	CcSEcCtD
Methamphetamine—SLC18A1—lymph node—breast cancer	0.00146	0.0305	CbGeAlD
Methamphetamine—SLC22A3—nipple—breast cancer	0.00114	0.0237	CbGeAlD
Methamphetamine—MAOB—nipple—breast cancer	0.00105	0.0219	CbGeAlD
Methamphetamine—SLC22A5—mammary gland—breast cancer	0.001	0.0208	CbGeAlD
Methamphetamine—SLC18A2—endometrium—breast cancer	0.000965	0.0201	CbGeAlD
Methamphetamine—SLC22A3—embryo—breast cancer	0.000939	0.0195	CbGeAlD
Methamphetamine—MAOA—nipple—breast cancer	0.000898	0.0187	CbGeAlD
Methamphetamine—SLC18A2—uterus—breast cancer	0.000889	0.0185	CbGeAlD
Methamphetamine—SLC18A2—adipose tissue—breast cancer	0.000869	0.0181	CbGeAlD
Methamphetamine—MAOB—embryo—breast cancer	0.000869	0.0181	CbGeAlD
Methamphetamine—ADRA2C—nipple—breast cancer	0.000864	0.018	CbGeAlD
Methamphetamine—Palpitations—Lapatinib—breast cancer	0.000863	0.0108	CcSEcCtD
Methamphetamine—Tremor—Toremifene—breast cancer	0.00083	0.0104	CcSEcCtD
Methamphetamine—SLC22A5—nipple—breast cancer	0.000827	0.0172	CbGeAlD
Methamphetamine—Hypersensitivity—Fluoxymesterone—breast cancer	0.000827	0.0103	CcSEcCtD
Methamphetamine—SLC18A2—female reproductive system—breast cancer	0.000799	0.0166	CbGeAlD
Methamphetamine—SLC18A2—adrenal gland—breast cancer	0.00078	0.0162	CbGeAlD
Methamphetamine—MAOA—embryo—breast cancer	0.000741	0.0154	CbGeAlD
Methamphetamine—Psychotic disorder—Goserelin—breast cancer	0.000735	0.00916	CcSEcCtD
Methamphetamine—Insomnia—Lapatinib—breast cancer	0.000721	0.00898	CcSEcCtD
Methamphetamine—Headache—Fluoxymesterone—breast cancer	0.000703	0.00877	CcSEcCtD
Methamphetamine—Dyspepsia—Lapatinib—breast cancer	0.000701	0.00874	CcSEcCtD
Methamphetamine—ADRA2A—nipple—breast cancer	0.000689	0.0143	CbGeAlD
Methamphetamine—Gastrointestinal disorder—Lapatinib—breast cancer	0.000688	0.00858	CcSEcCtD
Methamphetamine—SLC22A3—endometrium—breast cancer	0.000687	0.0143	CbGeAlD
Methamphetamine—Constipation—Lapatinib—breast cancer	0.000681	0.00849	CcSEcCtD
Methamphetamine—SLC18A2—endocrine gland—breast cancer	0.000676	0.0141	CbGeAlD
Methamphetamine—Insomnia—Fulvestrant—breast cancer	0.000663	0.00826	CcSEcCtD
Methamphetamine—Insomnia—Toremifene—breast cancer	0.000654	0.00816	CcSEcCtD
Methamphetamine—Dyspepsia—Fulvestrant—breast cancer	0.000645	0.00804	CcSEcCtD
Methamphetamine—MAOB—endometrium—breast cancer	0.000636	0.0132	CbGeAlD
Methamphetamine—Gastrointestinal disorder—Fulvestrant—breast cancer	0.000633	0.00789	CcSEcCtD
Methamphetamine—Euphoric mood—Fluorouracil—breast cancer	0.00063	0.00785	CcSEcCtD
Methamphetamine—Erectile dysfunction—Tamoxifen—breast cancer	0.000627	0.00781	CcSEcCtD
Methamphetamine—Constipation—Fulvestrant—breast cancer	0.000627	0.00781	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Toremifene—breast cancer	0.000624	0.00778	CcSEcCtD
Methamphetamine—SLC22A3—adipose tissue—breast cancer	0.000619	0.0129	CbGeAlD
Methamphetamine—Constipation—Toremifene—breast cancer	0.000619	0.00771	CcSEcCtD
Methamphetamine—Palpitations—Letrozole—breast cancer	0.000612	0.00763	CcSEcCtD
Methamphetamine—Erectile dysfunction—Goserelin—breast cancer	0.000599	0.00746	CcSEcCtD
Methamphetamine—Hypersensitivity—Lapatinib—breast cancer	0.000587	0.00732	CcSEcCtD
Methamphetamine—MAOB—uterus—breast cancer	0.000586	0.0122	CbGeAlD
Methamphetamine—Urticaria—Fulvestrant—breast cancer	0.000582	0.00726	CcSEcCtD
Methamphetamine—Insomnia—Exemestane—breast cancer	0.000576	0.00718	CcSEcCtD
Methamphetamine—MAOB—pituitary gland—breast cancer	0.000575	0.012	CbGeAlD
Methamphetamine—MAOB—adipose tissue—breast cancer	0.000573	0.0119	CbGeAlD
Methamphetamine—SLC22A3—female reproductive system—breast cancer	0.000569	0.0118	CbGeAlD
Methamphetamine—Dyspepsia—Exemestane—breast cancer	0.00056	0.00698	CcSEcCtD
Methamphetamine—SLC22A3—adrenal gland—breast cancer	0.000555	0.0116	CbGeAlD
Methamphetamine—SLC6A4—female reproductive system—breast cancer	0.000554	0.0115	CbGeAlD
Methamphetamine—Tachycardia—Letrozole—breast cancer	0.000552	0.00688	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Exemestane—breast cancer	0.00055	0.00685	CcSEcCtD
Methamphetamine—Diarrhoea—Lapatinib—breast cancer	0.000545	0.0068	CcSEcCtD
Methamphetamine—Constipation—Exemestane—breast cancer	0.000544	0.00679	CcSEcCtD
Methamphetamine—Insomnia—Ixabepilone—breast cancer	0.000543	0.00677	CcSEcCtD
Methamphetamine—MAOA—endometrium—breast cancer	0.000542	0.0113	CbGeAlD
Methamphetamine—Hypersensitivity—Fulvestrant—breast cancer	0.00054	0.00673	CcSEcCtD
Methamphetamine—SLC22A5—skin of body—breast cancer	0.00053	0.011	CbGeAlD
Methamphetamine—MAOB—female reproductive system—breast cancer	0.000527	0.011	CbGeAlD
Methamphetamine—ADRA2C—endometrium—breast cancer	0.000522	0.0109	CbGeAlD
Methamphetamine—Gastrointestinal disorder—Ixabepilone—breast cancer	0.000519	0.00646	CcSEcCtD
Methamphetamine—SLC22A3—female gonad—breast cancer	0.000518	0.0108	CbGeAlD
Methamphetamine—MAOB—adrenal gland—breast cancer	0.000514	0.0107	CbGeAlD
Methamphetamine—Constipation—Ixabepilone—breast cancer	0.000514	0.0064	CcSEcCtD
Methamphetamine—Insomnia—Anastrozole—breast cancer	0.000512	0.00638	CcSEcCtD
Methamphetamine—Insomnia—Letrozole—breast cancer	0.000512	0.00638	CcSEcCtD
Methamphetamine—Pseudoephedrine—IL2—breast cancer	0.000511	0.137	CrCbGaD
Methamphetamine—Urticaria—Exemestane—breast cancer	0.000506	0.0063	CcSEcCtD
Methamphetamine—Diarrhoea—Fulvestrant—breast cancer	0.000501	0.00625	CcSEcCtD
Methamphetamine—MAOA—uterus—breast cancer	0.0005	0.0104	CbGeAlD
Methamphetamine—SLC22A5—endometrium—breast cancer	0.0005	0.0104	CbGeAlD
Methamphetamine—Headache—Lapatinib—breast cancer	0.000499	0.00622	CcSEcCtD
Methamphetamine—Tremor—Chlorambucil—breast cancer	0.000499	0.00622	CcSEcCtD
Methamphetamine—Dyspepsia—Letrozole—breast cancer	0.000498	0.00621	CcSEcCtD
Methamphetamine—Dyspepsia—Anastrozole—breast cancer	0.000498	0.00621	CcSEcCtD
Methamphetamine—MAOA—pituitary gland—breast cancer	0.000491	0.0102	CbGeAlD
Methamphetamine—Agitation—Chlorambucil—breast cancer	0.00049	0.0061	CcSEcCtD
Methamphetamine—MAOA—adipose tissue—breast cancer	0.000489	0.0102	CbGeAlD
Methamphetamine—Gastrointestinal disorder—Letrozole—breast cancer	0.000488	0.00609	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Anastrozole—breast cancer	0.000488	0.00609	CcSEcCtD
Methamphetamine—SLC6A2—female reproductive system—breast cancer	0.000488	0.0101	CbGeAlD
Methamphetamine—Insomnia—Raloxifene—breast cancer	0.000485	0.00605	CcSEcCtD
Methamphetamine—Dizziness—Fulvestrant—breast cancer	0.000485	0.00604	CcSEcCtD
Methamphetamine—Constipation—Anastrozole—breast cancer	0.000484	0.00603	CcSEcCtD
Methamphetamine—Constipation—Letrozole—breast cancer	0.000484	0.00603	CcSEcCtD
Methamphetamine—SLC22A3—endocrine gland—breast cancer	0.000482	0.01	CbGeAlD
Methamphetamine—ADRA2C—uterus—breast cancer	0.000481	0.01	CbGeAlD
Methamphetamine—MAOB—female gonad—breast cancer	0.000479	0.00997	CbGeAlD
Methamphetamine—Dizziness—Toremifene—breast cancer	0.000478	0.00596	CcSEcCtD
Methamphetamine—SLC6A2—adrenal gland—breast cancer	0.000476	0.0099	CbGeAlD
Methamphetamine—Dyspepsia—Raloxifene—breast cancer	0.000473	0.00589	CcSEcCtD
Methamphetamine—ADRA2C—pituitary gland—breast cancer	0.000472	0.00982	CbGeAlD
Methamphetamine—ADRA2C—adipose tissue—breast cancer	0.00047	0.00978	CbGeAlD
Methamphetamine—Hypersensitivity—Exemestane—breast cancer	0.000469	0.00585	CcSEcCtD
Methamphetamine—SLC6A4—endocrine gland—breast cancer	0.000469	0.00976	CbGeAlD
Methamphetamine—SLC18A2—lymph node—breast cancer	0.000468	0.00973	CbGeAlD
Methamphetamine—Gastrointestinal disorder—Raloxifene—breast cancer	0.000463	0.00578	CcSEcCtD
Methamphetamine—Headache—Fulvestrant—breast cancer	0.000459	0.00572	CcSEcCtD
Methamphetamine—Headache—Toremifene—breast cancer	0.000453	0.00565	CcSEcCtD
Methamphetamine—SLC22A5—pituitary gland—breast cancer	0.000452	0.00941	CbGeAlD
Methamphetamine—SLC22A5—adipose tissue—breast cancer	0.00045	0.00937	CbGeAlD
Methamphetamine—MAOA—female reproductive system—breast cancer	0.000449	0.00935	CbGeAlD
Methamphetamine—Urticaria—Anastrozole—breast cancer	0.000449	0.0056	CcSEcCtD
Methamphetamine—Urticaria—Letrozole—breast cancer	0.000449	0.0056	CcSEcCtD
Methamphetamine—MAOB—endocrine gland—breast cancer	0.000446	0.00928	CbGeAlD
Methamphetamine—Hypersensitivity—Ixabepilone—breast cancer	0.000443	0.00552	CcSEcCtD
Methamphetamine—Erectile dysfunction—Mitoxantrone—breast cancer	0.000442	0.00551	CcSEcCtD
Methamphetamine—MAOA—adrenal gland—breast cancer	0.000439	0.00913	CbGeAlD
Methamphetamine—Diarrhoea—Exemestane—breast cancer	0.000436	0.00543	CcSEcCtD
Methamphetamine—Urticaria—Idarubicin—breast cancer	0.000426	0.00532	CcSEcCtD
Methamphetamine—ADRA2C—adrenal gland—breast cancer	0.000422	0.00877	CbGeAlD
Methamphetamine—Dizziness—Exemestane—breast cancer	0.000421	0.00525	CcSEcCtD
Methamphetamine—Hypersensitivity—Anastrozole—breast cancer	0.000417	0.00519	CcSEcCtD
Methamphetamine—ADRA2A—endometrium—breast cancer	0.000416	0.00866	CbGeAlD
Methamphetamine—SLC22A5—female reproductive system—breast cancer	0.000414	0.00861	CbGeAlD
Methamphetamine—SLC6A2—endocrine gland—breast cancer	0.000413	0.00859	CbGeAlD
Methamphetamine—Diarrhoea—Ixabepilone—breast cancer	0.000411	0.00512	CcSEcCtD
Methamphetamine—MAOA—female gonad—breast cancer	0.000409	0.00851	CbGeAlD
Methamphetamine—SLC22A5—adrenal gland—breast cancer	0.000404	0.0084	CbGeAlD
Methamphetamine—Palpitations—Goserelin—breast cancer	0.0004	0.00499	CcSEcCtD
Methamphetamine—Headache—Exemestane—breast cancer	0.000399	0.00497	CcSEcCtD
Methamphetamine—Ephedrine—ACHE—breast cancer	0.000399	0.107	CrCbGaD
Methamphetamine—Dizziness—Ixabepilone—breast cancer	0.000397	0.00495	CcSEcCtD
Methamphetamine—Hypersensitivity—Idarubicin—breast cancer	0.000395	0.00493	CcSEcCtD
Methamphetamine—ADRA2C—female gonad—breast cancer	0.000393	0.00818	CbGeAlD
Methamphetamine—Diarrhoea—Anastrozole—breast cancer	0.000387	0.00482	CcSEcCtD
Methamphetamine—Diarrhoea—Letrozole—breast cancer	0.000387	0.00482	CcSEcCtD
Methamphetamine—ADRA2A—uterus—breast cancer	0.000383	0.00798	CbGeAlD
Methamphetamine—Dyspepsia—Chlorambucil—breast cancer	0.000383	0.00477	CcSEcCtD
Methamphetamine—MAOA—endocrine gland—breast cancer	0.00038	0.00791	CbGeAlD
Methamphetamine—ADRA2A—pituitary gland—breast cancer	0.000377	0.00784	CbGeAlD
Methamphetamine—SLC22A5—female gonad—breast cancer	0.000377	0.00784	CbGeAlD
Methamphetamine—Headache—Ixabepilone—breast cancer	0.000376	0.00469	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Chlorambucil—breast cancer	0.000375	0.00468	CcSEcCtD
Methamphetamine—ADRA2A—adipose tissue—breast cancer	0.000375	0.00781	CbGeAlD
Methamphetamine—Dizziness—Anastrozole—breast cancer	0.000374	0.00466	CcSEcCtD
Methamphetamine—Dizziness—Letrozole—breast cancer	0.000374	0.00466	CcSEcCtD
Methamphetamine—Tachycardia—Melphalan—breast cancer	0.00037	0.00461	CcSEcCtD
Methamphetamine—Diarrhoea—Idarubicin—breast cancer	0.000367	0.00458	CcSEcCtD
Methamphetamine—Diarrhoea—Raloxifene—breast cancer	0.000367	0.00458	CcSEcCtD
Methamphetamine—Tachycardia—Goserelin—breast cancer	0.000361	0.0045	CcSEcCtD
Methamphetamine—Palpitations—Vinorelbine—breast cancer	0.000358	0.00447	CcSEcCtD
Methamphetamine—Agitation—Thiotepa—breast cancer	0.000356	0.00444	CcSEcCtD
Methamphetamine—Dizziness—Raloxifene—breast cancer	0.000355	0.00443	CcSEcCtD
Methamphetamine—Headache—Anastrozole—breast cancer	0.000354	0.00442	CcSEcCtD
Methamphetamine—Headache—Letrozole—breast cancer	0.000354	0.00442	CcSEcCtD
Methamphetamine—Insomnia—Tamoxifen—breast cancer	0.00035	0.00436	CcSEcCtD
Methamphetamine—Urticaria—Chlorambucil—breast cancer	0.000345	0.00431	CcSEcCtD
Methamphetamine—ADRA2A—female reproductive system—breast cancer	0.000345	0.00717	CbGeAlD
Methamphetamine—Constipation—Vinblastine—breast cancer	0.000341	0.00425	CcSEcCtD
Methamphetamine—Dyspepsia—Tamoxifen—breast cancer	0.000341	0.00425	CcSEcCtD
Methamphetamine—ADRA2A—adrenal gland—breast cancer	0.000336	0.007	CbGeAlD
Methamphetamine—Headache—Idarubicin—breast cancer	0.000336	0.00419	CcSEcCtD
Methamphetamine—Headache—Raloxifene—breast cancer	0.000336	0.00419	CcSEcCtD
Methamphetamine—Insomnia—Goserelin—breast cancer	0.000334	0.00417	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Tamoxifen—breast cancer	0.000334	0.00417	CcSEcCtD
Methamphetamine—Dyspepsia—Melphalan—breast cancer	0.000334	0.00416	CcSEcCtD
Methamphetamine—SLC22A3—lymph node—breast cancer	0.000333	0.00693	CbGeAlD
Methamphetamine—Constipation—Tamoxifen—breast cancer	0.000331	0.00413	CcSEcCtD
Methamphetamine—Lacosamide—SCN10A—breast cancer	0.000328	0.0881	CrCbGaD
Methamphetamine—Gastrointestinal disorder—Melphalan—breast cancer	0.000327	0.00408	CcSEcCtD
Methamphetamine—Dyspepsia—Goserelin—breast cancer	0.000325	0.00406	CcSEcCtD
Methamphetamine—Tachycardia—Vinorelbine—breast cancer	0.000323	0.00403	CcSEcCtD
Methamphetamine—Hypersensitivity—Chlorambucil—breast cancer	0.00032	0.00399	CcSEcCtD
Methamphetamine—Constipation—Goserelin—breast cancer	0.000316	0.00394	CcSEcCtD
Methamphetamine—ADRA2A—female gonad—breast cancer	0.000314	0.00653	CbGeAlD
Methamphetamine—Tachycardia—Thiotepa—breast cancer	0.000309	0.00385	CcSEcCtD
Methamphetamine—MAOB—lymph node—breast cancer	0.000308	0.00641	CbGeAlD
Methamphetamine—Urticaria—Tamoxifen—breast cancer	0.000307	0.00383	CcSEcCtD
Methamphetamine—Urticaria—Melphalan—breast cancer	0.000301	0.00375	CcSEcCtD
Methamphetamine—Lacosamide—CA9—breast cancer	0.0003	0.0806	CrCbGaD
Methamphetamine—Diarrhoea—Chlorambucil—breast cancer	0.000297	0.00371	CcSEcCtD
Methamphetamine—Urticaria—Goserelin—breast cancer	0.000294	0.00366	CcSEcCtD
Methamphetamine—Hypersensitivity—Vinblastine—breast cancer	0.000294	0.00366	CcSEcCtD
Methamphetamine—ADRA2A—endocrine gland—breast cancer	0.000292	0.00607	CbGeAlD
Methamphetamine—Gastrointestinal disorder—Vinorelbine—breast cancer	0.000286	0.00356	CcSEcCtD
Methamphetamine—SLC6A2—lymph node—breast cancer	0.000285	0.00594	CbGeAlD
Methamphetamine—Hypersensitivity—Tamoxifen—breast cancer	0.000285	0.00355	CcSEcCtD
Methamphetamine—Constipation—Vinorelbine—breast cancer	0.000283	0.00353	CcSEcCtD
Methamphetamine—Hypersensitivity—Melphalan—breast cancer	0.000279	0.00348	CcSEcCtD
Methamphetamine—Dyspepsia—Thiotepa—breast cancer	0.000278	0.00347	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Thiotepa—breast cancer	0.000273	0.0034	CcSEcCtD
Methamphetamine—Diarrhoea—Vinblastine—breast cancer	0.000273	0.0034	CcSEcCtD
Methamphetamine—Hypersensitivity—Goserelin—breast cancer	0.000272	0.0034	CcSEcCtD
Methamphetamine—Constipation—Thiotepa—breast cancer	0.00027	0.00337	CcSEcCtD
Methamphetamine—CYP2D6—female reproductive system—breast cancer	0.000267	0.00556	CbGeAlD
Methamphetamine—Tachycardia—Mitoxantrone—breast cancer	0.000266	0.00332	CcSEcCtD
Methamphetamine—Diarrhoea—Tamoxifen—breast cancer	0.000265	0.0033	CcSEcCtD
Methamphetamine—Dizziness—Vinblastine—breast cancer	0.000263	0.00328	CcSEcCtD
Methamphetamine—Urticaria—Vinorelbine—breast cancer	0.000263	0.00328	CcSEcCtD
Methamphetamine—MAOA—lymph node—breast cancer	0.000263	0.00547	CbGeAlD
Methamphetamine—Diarrhoea—Melphalan—breast cancer	0.000259	0.00323	CcSEcCtD
Methamphetamine—Dizziness—Tamoxifen—breast cancer	0.000256	0.00319	CcSEcCtD
Methamphetamine—Tremor—Paclitaxel—breast cancer	0.000256	0.00319	CcSEcCtD
Methamphetamine—Tachycardia—Fluorouracil—breast cancer	0.000255	0.00318	CcSEcCtD
Methamphetamine—Diarrhoea—Goserelin—breast cancer	0.000253	0.00315	CcSEcCtD
Methamphetamine—ADRA2C—lymph node—breast cancer	0.000253	0.00526	CbGeAlD
Methamphetamine—Urticaria—Thiotepa—breast cancer	0.000251	0.00313	CcSEcCtD
Methamphetamine—Agitation—Paclitaxel—breast cancer	0.000251	0.00313	CcSEcCtD
Methamphetamine—Headache—Vinblastine—breast cancer	0.00025	0.00311	CcSEcCtD
Methamphetamine—Insomnia—Irinotecan—breast cancer	0.000247	0.00308	CcSEcCtD
Methamphetamine—Dizziness—Goserelin—breast cancer	0.000244	0.00305	CcSEcCtD
Methamphetamine—Hypersensitivity—Vinorelbine—breast cancer	0.000244	0.00304	CcSEcCtD
Methamphetamine—CYP2D6—female gonad—breast cancer	0.000243	0.00506	CbGeAlD
Methamphetamine—Headache—Tamoxifen—breast cancer	0.000242	0.00302	CcSEcCtD
Methamphetamine—SLC22A5—lymph node—breast cancer	0.000242	0.00504	CbGeAlD
Methamphetamine—Palpitations—Paclitaxel—breast cancer	0.000241	0.00301	CcSEcCtD
Methamphetamine—Insomnia—Gemcitabine—breast cancer	0.000241	0.003	CcSEcCtD
Methamphetamine—Dyspepsia—Irinotecan—breast cancer	0.00024	0.003	CcSEcCtD
Methamphetamine—Dyspepsia—Mitoxantrone—breast cancer	0.00024	0.003	CcSEcCtD
Methamphetamine—Insomnia—Fluorouracil—breast cancer	0.000237	0.00295	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Irinotecan—breast cancer	0.000236	0.00294	CcSEcCtD
Methamphetamine—Ephedrine—BCHE—breast cancer	0.000234	0.0629	CrCbGaD
Methamphetamine—Constipation—Irinotecan—breast cancer	0.000233	0.00291	CcSEcCtD
Methamphetamine—Constipation—Mitoxantrone—breast cancer	0.000233	0.00291	CcSEcCtD
Methamphetamine—Hypersensitivity—Thiotepa—breast cancer	0.000233	0.0029	CcSEcCtD
Methamphetamine—Headache—Goserelin—breast cancer	0.000232	0.00289	CcSEcCtD
Methamphetamine—Dyspepsia—Fluorouracil—breast cancer	0.00023	0.00287	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Gemcitabine—breast cancer	0.00023	0.00286	CcSEcCtD
Methamphetamine—Constipation—Gemcitabine—breast cancer	0.000227	0.00284	CcSEcCtD
Methamphetamine—Diarrhoea—Vinorelbine—breast cancer	0.000227	0.00282	CcSEcCtD
Methamphetamine—CYP2D6—endocrine gland—breast cancer	0.000226	0.0047	CbGeAlD
Methamphetamine—Gastrointestinal disorder—Fluorouracil—breast cancer	0.000226	0.00281	CcSEcCtD
Methamphetamine—Erectile dysfunction—Methotrexate—breast cancer	0.00022	0.00275	CcSEcCtD
Methamphetamine—Dizziness—Vinorelbine—breast cancer	0.000219	0.00273	CcSEcCtD
Methamphetamine—Tachycardia—Paclitaxel—breast cancer	0.000217	0.00271	CcSEcCtD
Methamphetamine—Urticaria—Mitoxantrone—breast cancer	0.000217	0.0027	CcSEcCtD
Methamphetamine—Diarrhoea—Thiotepa—breast cancer	0.000216	0.0027	CcSEcCtD
Methamphetamine—Dexfenfluramine—CYP2D6—breast cancer	0.000214	0.0573	CrCbGaD
Methamphetamine—Tremor—Capecitabine—breast cancer	0.00021	0.00262	CcSEcCtD
Methamphetamine—Dizziness—Thiotepa—breast cancer	0.000209	0.00261	CcSEcCtD
Methamphetamine—Urticaria—Fluorouracil—breast cancer	0.000208	0.00259	CcSEcCtD
Methamphetamine—Headache—Vinorelbine—breast cancer	0.000207	0.00259	CcSEcCtD
Methamphetamine—Palpitations—Docetaxel—breast cancer	0.000204	0.00255	CcSEcCtD
Methamphetamine—ADRA2A—lymph node—breast cancer	0.000202	0.0042	CbGeAlD
Methamphetamine—Insomnia—Paclitaxel—breast cancer	0.000201	0.00251	CcSEcCtD
Methamphetamine—Hypersensitivity—Irinotecan—breast cancer	0.000201	0.00251	CcSEcCtD
Methamphetamine—Hypersensitivity—Mitoxantrone—breast cancer	0.000201	0.00251	CcSEcCtD
Methamphetamine—Headache—Thiotepa—breast cancer	0.000198	0.00247	CcSEcCtD
Methamphetamine—Palpitations—Capecitabine—breast cancer	0.000198	0.00247	CcSEcCtD
Methamphetamine—Dyspepsia—Paclitaxel—breast cancer	0.000196	0.00244	CcSEcCtD
Methamphetamine—Hypersensitivity—Fluorouracil—breast cancer	0.000193	0.0024	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Paclitaxel—breast cancer	0.000192	0.0024	CcSEcCtD
Methamphetamine—Constipation—Paclitaxel—breast cancer	0.00019	0.00237	CcSEcCtD
Methamphetamine—Diarrhoea—Mitoxantrone—breast cancer	0.000187	0.00233	CcSEcCtD
Methamphetamine—Diarrhoea—Irinotecan—breast cancer	0.000187	0.00233	CcSEcCtD
Methamphetamine—Tachycardia—Docetaxel—breast cancer	0.000184	0.0023	CcSEcCtD
Methamphetamine—Diarrhoea—Gemcitabine—breast cancer	0.000182	0.00227	CcSEcCtD
Methamphetamine—Dizziness—Irinotecan—breast cancer	0.000181	0.00225	CcSEcCtD
Methamphetamine—Diarrhoea—Fluorouracil—breast cancer	0.000179	0.00223	CcSEcCtD
Methamphetamine—Tachycardia—Capecitabine—breast cancer	0.000178	0.00222	CcSEcCtD
Methamphetamine—Urticaria—Paclitaxel—breast cancer	0.000177	0.00221	CcSEcCtD
Methamphetamine—Dizziness—Fluorouracil—breast cancer	0.000173	0.00216	CcSEcCtD
Methamphetamine—Pseudoephedrine—TNF—breast cancer	0.000172	0.0462	CrCbGaD
Methamphetamine—Headache—Mitoxantrone—breast cancer	0.000171	0.00213	CcSEcCtD
Methamphetamine—Headache—Irinotecan—breast cancer	0.000171	0.00213	CcSEcCtD
Methamphetamine—Insomnia—Docetaxel—breast cancer	0.000171	0.00213	CcSEcCtD
Methamphetamine—Headache—Gemcitabine—breast cancer	0.000167	0.00208	CcSEcCtD
Methamphetamine—Dyspepsia—Docetaxel—breast cancer	0.000166	0.00207	CcSEcCtD
Methamphetamine—Insomnia—Capecitabine—breast cancer	0.000165	0.00206	CcSEcCtD
Methamphetamine—Hypersensitivity—Paclitaxel—breast cancer	0.000164	0.00205	CcSEcCtD
Methamphetamine—Headache—Fluorouracil—breast cancer	0.000164	0.00204	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Docetaxel—breast cancer	0.000163	0.00203	CcSEcCtD
Methamphetamine—Constipation—Docetaxel—breast cancer	0.000161	0.00201	CcSEcCtD
Methamphetamine—Dyspepsia—Capecitabine—breast cancer	0.000161	0.00201	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Capecitabine—breast cancer	0.000158	0.00197	CcSEcCtD
Methamphetamine—Constipation—Capecitabine—breast cancer	0.000156	0.00195	CcSEcCtD
Methamphetamine—Diarrhoea—Paclitaxel—breast cancer	0.000152	0.0019	CcSEcCtD
Methamphetamine—Phenformin—CYP2D6—breast cancer	0.00015	0.0403	CrCbGaD
Methamphetamine—Dizziness—Paclitaxel—breast cancer	0.000147	0.00184	CcSEcCtD
Methamphetamine—Urticaria—Capecitabine—breast cancer	0.000145	0.00181	CcSEcCtD
Methamphetamine—Agitation—Epirubicin—breast cancer	0.000143	0.00179	CcSEcCtD
Methamphetamine—Headache—Paclitaxel—breast cancer	0.00014	0.00174	CcSEcCtD
Methamphetamine—Hypersensitivity—Docetaxel—breast cancer	0.000139	0.00173	CcSEcCtD
Methamphetamine—Palpitations—Epirubicin—breast cancer	0.000138	0.00172	CcSEcCtD
Methamphetamine—Hypersensitivity—Capecitabine—breast cancer	0.000135	0.00168	CcSEcCtD
Methamphetamine—Benzyl alcohol—CYP1A1—breast cancer	0.000133	0.0357	CrCbGaD
Methamphetamine—Agitation—Doxorubicin—breast cancer	0.000133	0.00165	CcSEcCtD
Methamphetamine—Diarrhoea—Docetaxel—breast cancer	0.000129	0.00161	CcSEcCtD
Methamphetamine—Palpitations—Doxorubicin—breast cancer	0.000128	0.00159	CcSEcCtD
Methamphetamine—Diarrhoea—Capecitabine—breast cancer	0.000125	0.00156	CcSEcCtD
Methamphetamine—Nateglinide—PTGS1—breast cancer	0.000125	0.0335	CrCbGaD
Methamphetamine—Dizziness—Docetaxel—breast cancer	0.000125	0.00156	CcSEcCtD
Methamphetamine—Tachycardia—Epirubicin—breast cancer	0.000124	0.00155	CcSEcCtD
Methamphetamine—Insomnia—Methotrexate—breast cancer	0.000123	0.00153	CcSEcCtD
Methamphetamine—Dizziness—Capecitabine—breast cancer	0.000121	0.00151	CcSEcCtD
Methamphetamine—Dyspepsia—Methotrexate—breast cancer	0.00012	0.00149	CcSEcCtD
Methamphetamine—Headache—Docetaxel—breast cancer	0.000118	0.00147	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Methotrexate—breast cancer	0.000117	0.00146	CcSEcCtD
Methamphetamine—Insomnia—Epirubicin—breast cancer	0.000115	0.00144	CcSEcCtD
Methamphetamine—Tachycardia—Doxorubicin—breast cancer	0.000115	0.00143	CcSEcCtD
Methamphetamine—Headache—Capecitabine—breast cancer	0.000114	0.00143	CcSEcCtD
Methamphetamine—Dyspepsia—Epirubicin—breast cancer	0.000112	0.0014	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Epirubicin—breast cancer	0.00011	0.00137	CcSEcCtD
Methamphetamine—Constipation—Epirubicin—breast cancer	0.000109	0.00136	CcSEcCtD
Methamphetamine—Urticaria—Methotrexate—breast cancer	0.000108	0.00135	CcSEcCtD
Methamphetamine—Insomnia—Doxorubicin—breast cancer	0.000107	0.00133	CcSEcCtD
Methamphetamine—Dyspepsia—Doxorubicin—breast cancer	0.000104	0.00129	CcSEcCtD
Methamphetamine—Phentermine—CYP2D6—breast cancer	0.000103	0.0276	CrCbGaD
Methamphetamine—Gastrointestinal disorder—Doxorubicin—breast cancer	0.000102	0.00127	CcSEcCtD
Methamphetamine—Urticaria—Epirubicin—breast cancer	0.000101	0.00126	CcSEcCtD
Methamphetamine—Constipation—Doxorubicin—breast cancer	0.000101	0.00126	CcSEcCtD
Methamphetamine—Hypersensitivity—Methotrexate—breast cancer	0.0001	0.00125	CcSEcCtD
Methamphetamine—Benzyl alcohol—CYP2D6—breast cancer	9.91e-05	0.0266	CrCbGaD
Methamphetamine—Dextroamphetamine—CYP2D6—breast cancer	9.81e-05	0.0263	CrCbGaD
Methamphetamine—Pseudoephedrine—CYP2D6—breast cancer	9.75e-05	0.0261	CrCbGaD
Methamphetamine—Selegiline—CYP2D6—breast cancer	9.51e-05	0.0255	CrCbGaD
Methamphetamine—Hypersensitivity—Epirubicin—breast cancer	9.38e-05	0.00117	CcSEcCtD
Methamphetamine—Urticaria—Doxorubicin—breast cancer	9.36e-05	0.00117	CcSEcCtD
Methamphetamine—Diarrhoea—Methotrexate—breast cancer	9.31e-05	0.00116	CcSEcCtD
Methamphetamine—Dizziness—Methotrexate—breast cancer	9e-05	0.00112	CcSEcCtD
Methamphetamine—Diarrhoea—Epirubicin—breast cancer	8.71e-05	0.00109	CcSEcCtD
Methamphetamine—Hypersensitivity—Doxorubicin—breast cancer	8.68e-05	0.00108	CcSEcCtD
Methamphetamine—Headache—Methotrexate—breast cancer	8.52e-05	0.00106	CcSEcCtD
Methamphetamine—Nateglinide—CYP2D6—breast cancer	8.5e-05	0.0228	CrCbGaD
Methamphetamine—Benzyl alcohol—CYP3A4—breast cancer	8.5e-05	0.0228	CrCbGaD
Methamphetamine—Dizziness—Epirubicin—breast cancer	8.42e-05	0.00105	CcSEcCtD
Methamphetamine—Selegiline—CYP3A4—breast cancer	8.16e-05	0.0219	CrCbGaD
Methamphetamine—Diarrhoea—Doxorubicin—breast cancer	8.06e-05	0.001	CcSEcCtD
Methamphetamine—Headache—Epirubicin—breast cancer	7.98e-05	0.000994	CcSEcCtD
Methamphetamine—Amphetamine—CYP2D6—breast cancer	7.91e-05	0.0212	CrCbGaD
Methamphetamine—Dizziness—Doxorubicin—breast cancer	7.79e-05	0.000971	CcSEcCtD
Methamphetamine—Headache—Doxorubicin—breast cancer	7.38e-05	0.00092	CcSEcCtD
Methamphetamine—Nateglinide—CYP3A4—breast cancer	7.29e-05	0.0196	CrCbGaD
Methamphetamine—Phenelzine—CYP3A4—breast cancer	7.19e-05	0.0193	CrCbGaD
Methamphetamine—Selegiline—ABCB1—breast cancer	6.79e-05	0.0182	CrCbGaD
Methamphetamine—Nateglinide—ALB—breast cancer	6.36e-05	0.0171	CrCbGaD
Methamphetamine—Benzphetamine—CYP3A4—breast cancer	6.23e-05	0.0167	CrCbGaD
Methamphetamine—ADRA2B—Signaling Pathways—ESR1—breast cancer	4.09e-06	3.19e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—SMAD4—breast cancer	4.07e-06	3.17e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—AKT1—breast cancer	4.07e-06	3.17e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IGF1R—breast cancer	4.05e-06	3.15e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—PIK3CA—breast cancer	4.04e-06	3.15e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—FN1—breast cancer	4.04e-06	3.15e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—CXCL8—breast cancer	4.03e-06	3.14e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PIK3CB—breast cancer	4.03e-06	3.13e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—SLC2A1—breast cancer	4.02e-06	3.13e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—NQO1—breast cancer	4.02e-06	3.13e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—LEP—breast cancer	4e-06	3.12e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NFKBIA—breast cancer	3.99e-06	3.11e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PTGS2—breast cancer	3.99e-06	3.11e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HES1—breast cancer	3.98e-06	3.1e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CAV1—breast cancer	3.97e-06	3.09e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NOTCH1—breast cancer	3.96e-06	3.08e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PLA2G4A—breast cancer	3.95e-06	3.08e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NCOR1—breast cancer	3.95e-06	3.08e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—KDR—breast cancer	3.92e-06	3.05e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CYP3A4—breast cancer	3.92e-06	3.05e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—TP53—breast cancer	3.91e-06	3.05e-05	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—PIK3CA—breast cancer	3.91e-06	3.04e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—FGF1—breast cancer	3.91e-06	3.04e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CSF2—breast cancer	3.91e-06	3.04e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—RAF1—breast cancer	3.9e-06	3.04e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NRG1—breast cancer	3.88e-06	3.02e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—KIT—breast cancer	3.87e-06	3.01e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PIK3CG—breast cancer	3.87e-06	3.01e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—APC—breast cancer	3.87e-06	3.01e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CAV1—breast cancer	3.85e-06	3e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CYP1B1—breast cancer	3.85e-06	3e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—H2AFX—breast cancer	3.85e-06	3e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—IL2—breast cancer	3.85e-06	3e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—E2F1—breast cancer	3.82e-06	2.98e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—EGF—breast cancer	3.82e-06	2.98e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—ESR1—breast cancer	3.82e-06	2.98e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—PIK3CB—breast cancer	3.81e-06	2.96e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PIK3CD—breast cancer	3.8e-06	2.96e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—HSP90AA1—breast cancer	3.78e-06	2.94e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—FN1—breast cancer	3.78e-06	2.94e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—ALB—breast cancer	3.75e-06	2.92e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—HRAS—breast cancer	3.74e-06	2.91e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NFKBIA—breast cancer	3.73e-06	2.9e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—MAPK3—breast cancer	3.7e-06	2.88e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NOTCH1—breast cancer	3.69e-06	2.88e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—NCOA1—breast cancer	3.68e-06	2.86e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—SPP1—breast cancer	3.67e-06	2.86e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CXCL8—breast cancer	3.66e-06	2.85e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—BRAF—breast cancer	3.64e-06	2.83e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ERBB3—breast cancer	3.63e-06	2.83e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—FGFR2—breast cancer	3.63e-06	2.83e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CYP19A1—breast cancer	3.62e-06	2.82e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—STK11—breast cancer	3.62e-06	2.82e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—KIT—breast cancer	3.61e-06	2.81e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—APC—breast cancer	3.61e-06	2.81e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PIK3CG—breast cancer	3.61e-06	2.81e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—NOS3—breast cancer	3.59e-06	2.79e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—EGF—breast cancer	3.57e-06	2.78e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IGF1—breast cancer	3.54e-06	2.76e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—AKT2—breast cancer	3.54e-06	2.76e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—EGFR—breast cancer	3.52e-06	2.74e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PIK3CG—breast cancer	3.51e-06	2.73e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—IL2—breast cancer	3.5e-06	2.72e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TERT—breast cancer	3.48e-06	2.71e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PTEN—breast cancer	3.48e-06	2.71e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—MAPK3—breast cancer	3.46e-06	2.69e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PIK3CD—breast cancer	3.4e-06	2.65e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—BRAF—breast cancer	3.4e-06	2.64e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—FGFR1—breast cancer	3.38e-06	2.63e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—PIK3CA—breast cancer	3.37e-06	2.62e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—COMT—breast cancer	3.37e-06	2.62e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—SERPINE1—breast cancer	3.36e-06	2.62e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GSTP1—breast cancer	3.35e-06	2.61e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HIF1A—breast cancer	3.33e-06	2.59e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—KRAS—breast cancer	3.33e-06	2.59e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PIK3CB—breast cancer	3.31e-06	2.58e-05	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—PIK3CA—breast cancer	3.31e-06	2.58e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IGF1—breast cancer	3.31e-06	2.58e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—AKT2—breast cancer	3.31e-06	2.57e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—HMOX1—breast cancer	3.31e-06	2.57e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—AKT1—breast cancer	3.3e-06	2.57e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ITPR1—breast cancer	3.3e-06	2.57e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—EGFR—breast cancer	3.29e-06	2.56e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PTGS2—breast cancer	3.28e-06	2.55e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—LEP—breast cancer	3.25e-06	2.53e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CAV1—breast cancer	3.22e-06	2.51e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NOS3—breast cancer	3.21e-06	2.5e-05	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—AKT1—breast cancer	3.19e-06	2.49e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—KDR—breast cancer	3.19e-06	2.48e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PIK3CD—breast cancer	3.18e-06	2.47e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ABCB1—breast cancer	3.17e-06	2.47e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—PIK3CA—breast cancer	3.15e-06	2.45e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—SERPINE1—breast cancer	3.14e-06	2.45e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—TYMS—breast cancer	3.12e-06	2.43e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—KRAS—breast cancer	3.11e-06	2.42e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ESR1—breast cancer	3.1e-06	2.42e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PIK3CD—breast cancer	3.09e-06	2.4e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GSTM1—breast cancer	3.08e-06	2.4e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—NCOR1—breast cancer	3.08e-06	2.4e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PLA2G4A—breast cancer	3.08e-06	2.4e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—FN1—breast cancer	3.07e-06	2.39e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—PIK3CA—breast cancer	3.06e-06	2.38e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MDM2—breast cancer	3.05e-06	2.37e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—ALB—breast cancer	3.05e-06	2.37e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—RAF1—breast cancer	3.04e-06	2.36e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NFKBIA—breast cancer	3.03e-06	2.36e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—RELA—breast cancer	3.02e-06	2.35e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—ERBB2—breast cancer	3e-06	2.34e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NOTCH1—breast cancer	3e-06	2.34e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NOS3—breast cancer	3e-06	2.34e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PIK3CB—breast cancer	2.96e-06	2.31e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MTOR—breast cancer	2.96e-06	2.31e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GPX1—breast cancer	2.95e-06	2.3e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PIK3CG—breast cancer	2.93e-06	2.28e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—KIT—breast cancer	2.93e-06	2.28e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—APC—breast cancer	2.93e-06	2.28e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CYP1A1—breast cancer	2.92e-06	2.27e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—NOS3—breast cancer	2.91e-06	2.27e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—EGF—breast cancer	2.9e-06	2.26e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ERCC2—breast cancer	2.9e-06	2.25e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PTEN—breast cancer	2.86e-06	2.23e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—PIK3CA—breast cancer	2.86e-06	2.22e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CXCL8—breast cancer	2.85e-06	2.22e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MDM2—breast cancer	2.85e-06	2.22e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—RAF1—breast cancer	2.84e-06	2.21e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—HRAS—breast cancer	2.83e-06	2.2e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—RELA—breast cancer	2.82e-06	2.2e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—MAPK3—breast cancer	2.81e-06	2.19e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—ERBB2—breast cancer	2.81e-06	2.18e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CDKN1B—breast cancer	2.78e-06	2.17e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MTOR—breast cancer	2.77e-06	2.16e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PIK3CB—breast cancer	2.77e-06	2.16e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—BRAF—breast cancer	2.76e-06	2.15e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—AKT1—breast cancer	2.75e-06	2.14e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CASP3—breast cancer	2.73e-06	2.12e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—MTHFR—breast cancer	2.72e-06	2.12e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL2—breast cancer	2.72e-06	2.12e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—IL6—breast cancer	2.71e-06	2.11e-05	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—AKT1—breast cancer	2.7e-06	2.1e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PIK3CB—breast cancer	2.69e-06	2.09e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IGF1—breast cancer	2.69e-06	2.09e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—AKT2—breast cancer	2.69e-06	2.09e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—EGFR—breast cancer	2.67e-06	2.08e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PTGS2—breast cancer	2.66e-06	2.07e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CXCL8—breast cancer	2.66e-06	2.07e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CCND1—breast cancer	2.65e-06	2.07e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—JUN—breast cancer	2.65e-06	2.06e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—HRAS—breast cancer	2.64e-06	2.06e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CTNNB1—breast cancer	2.63e-06	2.05e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CDKN1B—breast cancer	2.6e-06	2.02e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PIK3CD—breast cancer	2.58e-06	2.01e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MMP9—breast cancer	2.58e-06	2.01e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—AKT1—breast cancer	2.57e-06	2e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CDKN1A—breast cancer	2.57e-06	2e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PTEN—breast cancer	2.56e-06	1.99e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—PIK3CA—breast cancer	2.56e-06	1.99e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—SERPINE1—breast cancer	2.55e-06	1.99e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CASP3—breast cancer	2.55e-06	1.98e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL2—breast cancer	2.54e-06	1.98e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—IL6—breast cancer	2.53e-06	1.97e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—KRAS—breast cancer	2.53e-06	1.97e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CAV1—breast cancer	2.51e-06	1.95e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MAPK8—breast cancer	2.51e-06	1.95e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—AKT1—breast cancer	2.5e-06	1.95e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CCND1—breast cancer	2.48e-06	1.93e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—JUN—breast cancer	2.47e-06	1.93e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CTNNB1—breast cancer	2.45e-06	1.91e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PIK3CA—breast cancer	2.45e-06	1.91e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NOS3—breast cancer	2.44e-06	1.9e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MMP9—breast cancer	2.41e-06	1.87e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CDKN1A—breast cancer	2.4e-06	1.87e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PTEN—breast cancer	2.39e-06	1.86e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—SRC—breast cancer	2.38e-06	1.85e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MAPK8—breast cancer	2.34e-06	1.82e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—AKT1—breast cancer	2.33e-06	1.82e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PTEN—breast cancer	2.32e-06	1.81e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—PIK3CA—breast cancer	2.32e-06	1.81e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—VEGFA—breast cancer	2.31e-06	1.8e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MDM2—breast cancer	2.31e-06	1.8e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—RAF1—breast cancer	2.3e-06	1.79e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—RELA—breast cancer	2.29e-06	1.79e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—STAT3—breast cancer	2.29e-06	1.78e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PIK3CG—breast cancer	2.29e-06	1.78e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ERBB2—breast cancer	2.28e-06	1.77e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PIK3CB—breast cancer	2.25e-06	1.75e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MTOR—breast cancer	2.25e-06	1.75e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—SRC—breast cancer	2.22e-06	1.73e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MAPK3—breast cancer	2.19e-06	1.7e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CXCL8—breast cancer	2.16e-06	1.68e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—VEGFA—breast cancer	2.16e-06	1.68e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—HRAS—breast cancer	2.15e-06	1.67e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—STAT3—breast cancer	2.14e-06	1.67e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MYC—breast cancer	2.13e-06	1.66e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TGFB1—breast cancer	2.12e-06	1.65e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CDKN1B—breast cancer	2.11e-06	1.64e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—AKT1—breast cancer	2.09e-06	1.63e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—EGFR—breast cancer	2.08e-06	1.62e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CASP3—breast cancer	2.07e-06	1.61e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL2—breast cancer	2.07e-06	1.61e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—IL6—breast cancer	2.06e-06	1.6e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MAPK3—breast cancer	2.04e-06	1.59e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PIK3CA—breast cancer	2.02e-06	1.57e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CCND1—breast cancer	2.01e-06	1.57e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PIK3CD—breast cancer	2.01e-06	1.57e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—JUN—breast cancer	2.01e-06	1.56e-05	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—AKT1—breast cancer	2e-06	1.56e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CTNNB1—breast cancer	1.99e-06	1.55e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MYC—breast cancer	1.99e-06	1.55e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ALB—breast cancer	1.98e-06	1.55e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TGFB1—breast cancer	1.98e-06	1.54e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—KRAS—breast cancer	1.97e-06	1.53e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MMP9—breast cancer	1.95e-06	1.52e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CDKN1A—breast cancer	1.95e-06	1.52e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—EGFR—breast cancer	1.94e-06	1.51e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PTEN—breast cancer	1.94e-06	1.51e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MAPK8—breast cancer	1.9e-06	1.48e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—NOS3—breast cancer	1.9e-06	1.48e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—AKT1—breast cancer	1.9e-06	1.48e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—KRAS—breast cancer	1.84e-06	1.43e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PIK3CA—breast cancer	1.81e-06	1.41e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—SRC—breast cancer	1.8e-06	1.4e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—VEGFA—breast cancer	1.76e-06	1.37e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PIK3CB—breast cancer	1.75e-06	1.36e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TP53—breast cancer	1.75e-06	1.36e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—STAT3—breast cancer	1.74e-06	1.35e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PTGS2—breast cancer	1.74e-06	1.35e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PIK3CA—breast cancer	1.69e-06	1.31e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—HRAS—breast cancer	1.67e-06	1.3e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MAPK3—breast cancer	1.66e-06	1.29e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—AKT1—breast cancer	1.65e-06	1.28e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PIK3CA—breast cancer	1.64e-06	1.28e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TP53—breast cancer	1.63e-06	1.27e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MYC—breast cancer	1.61e-06	1.26e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TGFB1—breast cancer	1.61e-06	1.25e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL6—breast cancer	1.6e-06	1.25e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—EGFR—breast cancer	1.58e-06	1.23e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—HRAS—breast cancer	1.56e-06	1.22e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PTEN—breast cancer	1.51e-06	1.18e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL6—breast cancer	1.49e-06	1.16e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—KRAS—breast cancer	1.49e-06	1.16e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—AKT1—breast cancer	1.48e-06	1.15e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—AKT1—breast cancer	1.38e-06	1.07e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PIK3CA—breast cancer	1.37e-06	1.07e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—AKT1—breast cancer	1.34e-06	1.04e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TP53—breast cancer	1.33e-06	1.03e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HRAS—breast cancer	1.27e-06	9.87e-06	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL6—breast cancer	1.21e-06	9.45e-06	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—AKT1—breast cancer	1.12e-06	8.72e-06	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PIK3CA—breast cancer	1.07e-06	8.32e-06	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—AKT1—breast cancer	8.73e-07	6.79e-06	CbGpPWpGaD
